GLAND
Gland Pharma
Each stock's 10,000-path forecast, rendered as light.
Gland Pharma (GLAND) Stock Analysis & Case Study
Is GLAND a good buy? The data-driven verdict.
Gland Pharma (GLAND) trades at ₹2,187,on the numbers it tread carefully, a Downstox Snapshot Score of 39/100.
On the numbers, Gland Pharma (GLAND) tread carefully, a Downstox Snapshot Score of 39/100, weighing premium at 34.6× earnings, ROE of 10.7%, a 55% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
GLAND fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is GLAND overvalued? GLAND P/E vs its sector
GLAND's P/E of 34.6× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.82% dividend yield is below the peer median of 1.65%.
GLAND share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of GLAND history (10%/yr drift, 31%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| GLAND 2027 | ₹1,552 | ₹2,286 | ₹3,400 | +4% |
| GLAND 2028 | ₹1,379 | ₹2,414 | ₹4,197 | +10% |
| GLAND 2029 | ₹1,265 | ₹2,549 | ₹5,030 | +16% |
| GLAND 2030 | ₹1,170 | ₹2,644 | ₹5,911 | +20% |
| GLAND 2031 | ₹1,131 | ₹2,788 | ₹6,870 | +27% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability GLAND goes up, or doubles?
The bull case for GLAND
- Gland Pharma is part of the nifty100 universe with live, tracked fundamentals on Downstox.
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹5,030.
The bear case & risks
- At 34.6× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished.
- Return on equity is a soft 10.7%, capital efficiency trails higher-quality peers.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹1,265.
GLAND volatility & expected range, how bumpy is the ride?
Over the last 2.0 years GLAND compounded at 10%/year with annualized volatility of 31%. That volatility implies a 1-year 80% range of ₹1,552–₹3,400, the honest backbone behind any single price target.
GLAND price forecast, the full 60-month probability fan
GLAND price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds GLAND hits common targets within the simulated horizon?
Full multi-horizon detail on the GLAND price target & forecast page.
GLAND Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. GLAND scores 4/9,mixed financial health.
GLAND MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy GLAND with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| UpstoxCHEAPEST | 30.8% | 3.2× |
| ZerodhaCHEAPEST | 30.8% | 3.2× |
| DhanCHEAPEST | 30.8% | 3.2× |
Compare every broker on the GLAND MTF page.
GLAND vs peers,sector comparison
About Gland Pharma: sector, index & market-cap context
Gland Pharma (GLAND) is a mid-cap NSE-listed company, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹36,088 Cr. See more Nifty 100 stocks.
How the GLAND Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Gland Pharma's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
GLAND analysis, FAQs
Is Gland Pharma (GLAND) a good buy?
On the numbers, Gland Pharma (GLAND) tread carefully, a Downstox Snapshot Score of 39/100, weighing premium at 34.6× earnings, ROE of 10.7%, a 55% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is GLAND overvalued or undervalued?
GLAND trades at 34.6× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the GLAND share price target for 2031?
GLAND's probability-weighted 2031 median target is ₹2,788, with an 80% range of ₹1,131–₹6,870 (10,000-path Monte-Carlo).
What is the probability GLAND doubles in 5 years?
The modelled probability of GLAND reaching ₹4,398 (2×) within 5 years is 26%.
What is the bull case for GLAND?
Gland Pharma is part of the nifty100 universe with live, tracked fundamentals on Downstox.
What are the risks in GLAND?
At 34.6× earnings the stock carries a premium to the market, strong growth is already in the price, so any miss tends to be punished. Return on equity is a soft 10.7%, capital efficiency trails higher-quality peers.